Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$2.26
Day's Change
-0.2067 (-8.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.31
Day's Low
2.16
Volume
(Heavy Day)

Today's volume of 168,941 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.

168,941

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Torrid Holdings, Inc. - CURV

1:03 pm ET January 17, 2023 (Newsfile) Print

New York, New York--(Newsfile Corp. - January 17, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Torrid Holdings, Inc.("Torrid" or the "Company") (NYSE: CURV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Torrid and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On or around July 1, 2021, Torrid conducted its initial public offering ("IPO"), offering 12.65 million shares at a price of $21 per share (the "IPO Price"). Then, on September 7, 2022, Torrid issued a release announcing the Company's financial results for its second fiscal quarter ended July 30, 2022. The release revised downward Torrid's annual 2022 net sales guidance from a range of $1.3 billion to $1.365 billion to a range of $1.26 billion to $1.3 billion, which would be essentially flat year-over-year, and revised downward Torrid's annual 2022 adjusted EBITDA guidance from a range of $195 million to $220 million to a range of $160 million to $175 million, which would be significantly worse than Torrid's fiscal 2021 adjusted EBITDA of $246 million.

By the end of September 2022, the price of Torrid stock fell to a low of just $4.06 per share, over 80% below the IPO Price.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/151582

comtex tracking

COMTEX_422829325/2523/2023-01-17T13:03:57

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.